D. Western Therapeutics Institute, Inc.
Bondlido’s U.S. sales partnership and listing timing
Update on Bondlido's U.S. sales partnership and listing timing outlook. Expectation of contract signing in September and a change to the listing timing to the fourth quarter of 2026. Reassessment of sales conditions and revenue-sharing remains uncertain during the period. Impact on the FY2026 earnings guidance is unclear, but will be disclosed promptly as soon as determined.
Key Figures
- Possibility of revenue distribution from Bondlido
- Delay in signing the Sales License Agreement (September expectation)
- Confirmation of listing timing change to the fourth quarter of 2026
AI要約
Section heading
This material explains the latest status of Bondlido's U.S. sales partnership and listing timing. It outlines the progress of reconsidering the joint development with MedRx and the sales partnership terms with Terrain Pharmaceuticals, reasons for the contract signing delay, and changes to the current listing timing. Revisions to contract terms are taking time, and while a sales license agreement is expected to be signed in September, an acceleration is unlikely. The listing timing has not changed to the fourth quarter of 2026.
Section 2 heading
Bondlido's U.S. revenue outlook remains uncertain, with potential contingent revenue distributions depending on contract terms, but impact on the FY2026 earnings forecast remains uncertain. Future decisions and changes to contract terms will be promptly disclosed, and sales strategy and supply plans will continue to be reviewed.
D. Western Therapeutics Institute, Inc.
Company overview · Stock price · Financial data · All IR
